Detailed Information on Publication Record
2023
Salicylanilides and Their Anticancer Properties
KAUEROVÁ, Tereza, Maria-Jesus PEREZ-PEREZ and Peter KOLLÁRBasic information
Original name
Salicylanilides and Their Anticancer Properties
Authors
KAUEROVÁ, Tereza (203 Czech Republic, belonging to the institution), Maria-Jesus PEREZ-PEREZ and Peter KOLLÁR (203 Czech Republic, guarantor, belonging to the institution)
Edition
International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2023, 1422-0067
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.600 in 2022
RIV identification code
RIV/00216224:14160/23:00132228
Organization unit
Faculty of Pharmacy
UT WoS
000914982800001
Keywords in English
salicylanilides; anticancer properties; mitochondrial uncoupling; TK EGFR; STAT3; drug repurposing; niclosamide
Tags
International impact, Reviewed
Změněno: 5/4/2024 07:35, Mgr. Daniela Černá
Abstract
V originále
Salicylanilides are pharmacologically active compounds with a wide spectrum of biological effects. Halogenated salicylanilides, which have been used for decades in human and veterinary medicine as anthelmintics, have recently emerged as candidates for drug repurposing in oncology. The most prominent example of salicylanilide anthelmintic, that is intensively studied for its potential anticancer properties, is niclosamide. Nevertheless, recent studies have discovered extensive anticancer potential in a number of other salicylanilides. This potential of their anticancer action is mediated most likely by diverse mechanisms of action such as uncoupling of oxidative phosphorylation, inhibition of protein tyrosine kinase epidermal growth factor receptor, modulation of different signaling pathways as Wnt/beta-catenin, mTORC1, STAT3, NF-kappa B and Notch signaling pathways or induction of B-Raf V600E inhibition. Here we provide a comprehensive overview of the current knowledge about the proposed mechanisms of action of anticancer activity of salicylanilides based on preclinical in vitro and in vivo studies, or structural requirements for such an activity.